6.2 Bloodborne Pathogens & High-Consequence Infectious Diseases

Bloodborne Pathogens & High-Consequence Infectious Diseases

Quick Answer: The three primary bloodborne pathogens of concern in dentistry are Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), and Human Immunodeficiency Virus (HIV). The risk of transmission following a percutaneous needlestick from an infected source is highest for HBV (up to 30%), intermediate for HCV (~0.2%), and lowest for HIV (~0.3%). Employers must offer the HBV vaccine series free of charge within 10 working days of clinical hire, followed by anti-HBs titer testing 1–2 months post-series. Patients with active pulmonary tuberculosis cannot receive elective dental care.

Dental healthcare personnel (DHCP) face daily occupational risks involving sharp instruments, high-speed rotary cutting tools, and blood/saliva-contaminated aerosols. Understanding the transmission dynamics, environmental stability, and clinical protocols for high-consequence pathogens is vital for passing the DANB NELDA ICE exam and ensuring clinical safety.

---

Medical History and Infection-Control Decisions

Review and update the patient’s medical history at every visit before selecting precautions or deciding whether care should proceed. Ask about current infectious symptoms or diagnoses, recent fever or productive cough, tuberculosis evaluation, immune suppression, bloodborne infections, medications that affect immunity, vaccination status when clinically relevant, recent hospitalization, indwelling devices, and allergies to latex, disinfectants, or medications. Record the patient’s responses accurately, date the update, and alert the dentist to a change that may affect care.

A disclosed diagnosis never replaces Standard Precautions and never justifies weaker protection for another patient. The team treats blood, saliva, mucous membranes, and contaminated items according to the same baseline precautions whether or not infection is known. The history instead helps identify additional actions: postponing elective treatment for active infectious tuberculosis or another transmissible illness, using Transmission-Based Precautions and an appropriate facility for urgent care, arranging a medical consultation, modifying scheduling, or selecting latex-free supplies.

Use neutral, confidential questions and collect only information needed for safe care. Do not mark charts, doors, or schedules with stigmatizing labels. Protect health information under applicable privacy rules, and share it only with personnel who need it for treatment, safety, or authorized reporting. If a patient declines to answer, notify the dentist and document the refusal rather than guessing.

A screening answer is not a diagnosis. A cough does not prove tuberculosis, and a history of treated infection does not prove current infectivity. When disease status affects whether elective care can proceed, obtain direction from the treating physician or public-health authority. In an emergency, use the highest appropriate controls while arranging care at a facility equipped for the transmission route.

---

1. Viral Hepatitis: Comparative Analysis (HBV, HCV, HDV)

Viral hepatitis causes inflammation and necrosis of hepatic tissue. In dental settings, parenterally transmitted viruses (HBV, HCV, and HDV) represent major occupational threats.

                  VIRAL HEPATITIS TRANSMISSION MODES
   +-------------------------------------------------------------------------+
   | HEPATITIS A & E | Enteric (Fecal-Oral) route; contaminated water/food.  |
   |                 | NOT bloodborne; low occupational risk in dentistry.   |
   +-------------------------------------------------------------------------+
   | HEPATITIS B,    | Bloodborne & Parenteral (Percutaneous, mucosal,       |
   | C & D           | sexual transmission). MAJOR occupational threat.      |
   +-------------------------------------------------------------------------+

Hepatitis B Virus (HBV)

• Microbial Characteristics: Enveloped, partially double-stranded DNA virus (family Hepadnaviridae). Exceptionally hardy in the environment, capable of surviving and remaining infectious on dry environmental surfaces for at least 7 days.
• Modes of Transmission: Percutaneous injury (needlestick, contaminated bur), mucosal splash to eyes/mouth, non-intact skin exposure to blood, saliva contaminated with blood, or wound exudates.
• Transmission Risk: If a healthcare worker sustains a needlestick from a source patient positive for Hepatitis B e-antigen (HBeAg), the risk of clinical infection is 22% to 31% (approx. 30%). If the source is HBsAg-positive but HBeAg-negative, the risk is 1% to 6%.
• Clinical Sequelae: Causes acute hepatitis; 5–10% of infected adults progress to chronic carrier status, with lifelong risks of liver cirrhosis, liver failure, and hepatocellular carcinoma (liver cancer).

OSHA Hepatitis B Vaccine Mandate (29 CFR 1910.1030)

Under the OSHA Bloodborne Pathogens Standard, dental employers must comply with strict vaccination requirements:

1. Timeline: Must be offered to all employees with occupational exposure within 10 working days of initial assignment.
2. Financial Cost: Provided at no cost to the employee (paid entirely by the employer).
3. Administration: Administered as an intramuscular 3-dose series (typically at 0, 1, and 6 months) into the deltoid muscle (not the gluteal region, which reduces antibody response).
4. Post-Vaccination Serologic Testing: Mandatory testing for anti-HBs (Hepatitis B surface antibody) must be performed 1 to 2 months after completing the third dose.
   • Responders: Serum anti-HBs titer ≥ 10 mIU/mL indicates life-long protective immunity; no routine booster doses are currently recommended by the CDC for immunocompetent individuals.
   • Non-Responders: Employees with titers < 10 mIU/mL must receive a second complete 3-dose series (or challenge dose followed by retesting). If still non-responsive, they are classified as non-responders and require Hepatitis B Immune Globulin (HBIG) upon any occupational exposure.
5. Declination Form: If an employee refuses the vaccine, they must sign the official OSHA Hepatitis B Vaccine Declination Statement. The employee retains the legal right to request and receive the vaccine series at any future date at employer expense.

                    HEPATITIS B SEROLOGIC MARKERS
   +-------------------------------------------------------------------------+
   | HBsAg   | Hepatitis B Surface Antigen  --> Active ongoing infection    |
   | Anti-HBs| Hepatitis B Surface Antibody --> Immunity (Vaccine or Cured) |
   | HBcAg   | Hepatitis B Core Antigen     --> Intracellular viral core     |
   | Anti-HBc| Hepatitis B Core Antibody    --> Natural Infection marker     |
   | HBeAg   | Hepatitis B "e" Antigen      --> High replication & contagion |
   +-------------------------------------------------------------------------+

Hepatitis C Virus (HCV)

• Microbial Characteristics: Enveloped, single-stranded RNA virus (family Flaviviridae). Moderate environmental stability (survives 16 hours to 4 days on dry surfaces).
• Transmission Risk: Transmission risk following a percutaneous sharps injury from an HCV-positive source is approximately 0.2% under current CDC occupational-exposure guidance.
• Clinical Impact: 75% to 85% of infected individuals develop chronic infection. Chronic HCV is the leading indication for liver transplantation in the United States.
• Vaccine & Treatment: There is NO vaccine available for Hepatitis C. Treatment consists of curative direct-acting antiviral (DAA) medications taken orally for 8–12 weeks.

Hepatitis D Virus (HDV / Delta Agent)

• Defective Virus: A small, single-stranded RNA virus that is structurally incomplete. It requires the presence of Hepatitis B Virus (HBsAg) to manufacture its protein envelope and replicate.
• Infection Dynamics: Can occur as a simultaneous coinfection with HBV or as a superinfection in an existing chronic HBV carrier. Superinfection often results in fulminant, rapidly fatal hepatitis.
• Immunization: Immunization against Hepatitis B automatically confers complete immunity against Hepatitis D, because HDV cannot propagate without HBV.

---

2. Human Immunodeficiency Virus (HIV) & AIDS

• Microbial Structure: Enveloped retrovirus containing single-stranded RNA and the enzyme reverse transcriptase, which converts viral RNA into host proviral DNA within human CD4+ T-helper lymphocytes.
• Environmental Fragility: HIV is an extremely fragile virus that is rapidly inactivated (within seconds to minutes) by standard surface disinfectants, heat, and air drying. It poses virtually zero transmission risk via intact skin or environmental operatory surfaces.
• Occupational Transmission Risk:
  • Percutaneous Sharps Exposure: Average transmission risk is 0.3% (approx. 1 infection per 300 needlestick injuries from an untreated, viremic source).
  • Mucous Membrane Splash: Average transmission risk is 0.09% (less than 1 in 1,000).
• Pathophysiology & Progression: Progressive destruction of CD4+ T-lymphocytes leads to profound immunodeficiency. Acquired Immunodeficiency Syndrome (AIDS) is diagnosed when the CD4 count drops below 200 cells/µL (normal: 500–1,500 cells/µL) or upon the clinical presentation of AIDS-defining opportunistic conditions (e.g., Pneumocystis jirovecii pneumonia, Kaposi sarcoma, esophageal candidiasis, Mycobacterium avium complex).

---

3. Percutaneous Sharps Injury Transmission Risk Comparison

          PERCUTANEOUS TRANSMISSION RISK HIERARCHY ("RULE OF 3s")

      [ HEPATITIS B (HBV) ]  ===========>  ~ 30.0%  (Up to 31% if HBeAg+)
      [ HEPATITIS C (HCV) ]  ===========>  ~  0.2%  (Current CDC estimate)
      [ HIV               ]  ===========>  ~  0.3%  (3 in 1,000)

---

4. Tuberculosis (TB) & Respiratory Airborne Pathogens

Mycobacterium tuberculosis

• Bacterial Characteristics: Acid-fast, obligate aerobic, rod-shaped bacillus with a waxy, lipid-rich cell wall containing mycolic acid. This waxy coating provides immense resistance to chemical disinfectants, desiccation, and water-soluble antibiotics.
• Transmission: Transmitted via microscopic airborne droplet nuclei (1 to 5 µm) produced when an infected individual coughs, sneezes, speaks, or sings. Droplet nuclei remain suspended in room air currents for hours and bypass upper respiratory cilia to penetrate deep pulmonary alveoli.
• Latent TB Infection (LTBI) vs. Active TB Disease:
  • LTBI: Patient harbors live bacilli walled off in calcified granulomas (Ghon complexes); asymptomatic, non-infectious, normal chest radiograph, positive PPD skin test or IGRA blood test. Can receive routine dental care.
  • Active TB Disease: Bacilli actively multiplying in lungs; cough, hemoptysis (coughing blood), night sweats, weight loss, fever, abnormal chest radiograph; highly contagious.

Dental Management Protocol for Tuberculosis

1. Elective Dental Care: Strictly contraindicated for patients with active, infectious tuberculosis until evaluated by a physician and determined noninfectious by a qualified physician or public-health authority under current criteria.
2. Emergency Dental Care: If urgent emergency dental care cannot be postponed, treatment must NOT be performed in a standard outpatient operatory. It must be performed in a hospital or facility equipped with an Airborne Infection Isolation Room (AIIR) featuring negative air pressure (at least 6–12 air changes per hour) with air exhausted directly outside through HEPA filtration.
3. Respiratory PPE: Standard surgical masks DO NOT filter 1–5 µm droplet nuclei. Clinicians must wear a fit-tested, NIOSH-approved N95 particulate filtering facepiece respirator (or higher).
4. Disinfectant Benchmark: Because M. tuberculosis possesses extreme chemical resistance, the EPA requires hospital-grade surface disinfectants to prove tuberculocidal activity to achieve intermediate-level classification.

---

5. Herpesviruses & Waterborne Pathogens in Dentistry

Herpes Simplex Viruses (HSV)

• Herpes Simplex Virus Type 1 (HSV-1): Causes oral vesicular lesions.
  • Primary Herpetic Gingivostomatitis: Initial infection, common in young children; widespread painful intraoral vesicles that rupture into ulcerations, accompanied by high fever and lymphadenopathy.
  • Recurrent Herpes Labialis (Cold Sores / Fever Blisters): Reactivation of latent HSV-1 residing in the trigeminal ganglion (CN V). Clusters of fluid-filled vesicles on the vermilion border of lips; highly contagious during the vesicle and weeping stages. Elective dental treatment should be rescheduled until crusting and complete healing occur.
  • Herpetic Whitlow: Extremely painful HSV-1 or HSV-2 infection of the terminal finger or nail bed, historically acquired by dental personnel working without gloves in patient mouths containing active herpes lesions. Manifests as throbbing erythema, edema, and deep clusters of vesicles on the digits.

Other Clinically Significant Herpesviruses

• Varicella-Zoster Virus (VZV): Causes chickenpox (primary) and herpes zoster / shingles (reactivation along sensory dermatomes).
• Epstein-Barr Virus (EBV): Etiologic agent of infectious mononucleosis and oral hairy leukoplakia (white corrugated patches on lateral tongue borders in HIV/immunocompromised patients).

Legionella pneumophila in Dental Waterlines

• Gram-negative aerobic bacillus naturally colonizing municipal aquatic supplies and dental unit waterlines (DUWLs). Inhaling contaminated aerosols can cause Legionnaires' disease (a severe, potentially fatal pneumonia) or Pontiac fever (a self-limiting flu-like illness). DUWL management protocols (Section 7.3) prevent this transmission.

---

6. Occupational Post-Exposure Protocol (Sharps Injury / Splash)

When a percutaneous needlestick, scalpel cut, or mucosal splash occurs, immediate protocol compliance is mandatory:

                  POST-EXPOSURE INCIDENT ACTION TIMELINE

    [ STEP 1: IMMEDIATE FIRST AID ]
    • Wash puncture/wound thoroughly with soap and lukewarm water.
    • Flush eye/mucosa at eyewash station with sterile saline/water for 15 min.
    • DO NOT squeeze, suck, or apply bleach/caustic antiseptics to wound.
                    |
                    v
    [ STEP 2: REPORT & DOCUMENT ]
    • Immediately report incident to designated office Exposure Control Manager.
    • Document date, time, task performed, instrument involved, anatomical site.
                    |
                    v
    [ STEP 3: SOURCE PATIENT EVALUATION ]
    • Request source patient consent for voluntary serologic testing (HBV, HCV, HIV).
    • Source testing must comply with state confidentiality and privacy laws.
                    |
                    v
    [ STEP 4: MEDICAL EVALUATION & PEP ]
    • Exposed worker dispatched immediately to licensed healthcare professional.
    • HBV PEP: HBIG and/or vaccine series administered ideally within 24 hours.
    • HIV PEP: 3-drug antiretroviral therapy initiated within 2 HOURS (max 72 hrs).
    • Baseline worker testing; follow-up testing at 6 weeks, 12 weeks, 6 months.

---

7. Clinical Practice Traps & DANB Exam Pearls

[!CAUTION] DANB Exam Trap #1: First Aid for Percutaneous Injury When a sharps injury occurs, never apply bleach, glutaraldehyde, or caustic chemical agents to the wound, and do not aggressively squeeze or milk the site. The correct protocol is to gently wash the area with antimicrobial or non-antimicrobial soap and water.

[!WARNING] DANB Exam Trap #2: Hepatitis B Vaccine Titer Timing Questions frequently ask when post-vaccine titer testing must be conducted. The correct answer is 1 to 2 months after the third dose. Testing earlier than 30 days or later than 6 months can yield inaccurate assessments of acute seroconversion.

[!NOTE] DANB Exam Trap #3: HIV vs. HBV Needlestick Transmission Probability Do not overestimate HIV risk compared to HBV! The transmission probability of HIV via needlestick is roughly 0.3% (1 in 300), while HBV transmission from an HBeAg-positive source is nearly 100 times higher (~30%).